Dual-phase [18F]FDG PET/CT imaging in cervical carcinoma: enhanced metabolic characterization and novel prognostic indicators - a prospective study with paradigm-shifting clinical implications.
Accurate staging and metabolic characterization of cervical cancer remains challenging despite advances in imaging. This study investigates the diagnostic utility of dual-phase [18F]FDG PET/CT in cervical carcinoma, with an emphasis on metabolic biomarkers and prognostic indicators.
A prospective study of 50 patients with histopathologically proven cervical cancer was conducted over 24 months. Patients underwent dual-phase [18F]FDG PET/CT imaging with initial whole-body acquisition at 40-60 minutes post-injection and delayed imaging at 120 minutes post-injection following intravenous furosemide administration. Standardized uptake values (SUV), lesion detection efficacy, lymph node characterization, and extra-pelvic metastatic patterns were analyzed using paired t-tests and chi-square analysis.
Mean SUV in initial images (9.074 ± 6.113) increased significantly to 12.964 ± 7.494 in delayed images (p < 0.001), representing a 42.8% increase in metabolic activity. Delayed imaging detected primary lesions in 48 cases (96%) versus 44 cases (88%) on initial imaging, demonstrating superior sensitivity (91.7%) and specificity (100%). Critically, seven patients (14%) demonstrated lymph node visualization only on delayed imaging, and 14% exhibited SUV kinetics consistent with high-grade malignancy. Parametrial involvement occurred in 66% of cases, with 81.8% demonstrating bilateral involvement. Extra-pelvic metastases including supraclavicular lymphadenopathy (10%), hepatic involvement (10%), and skeletal lesions (8%) were detected with superior specificity compared to conventional modalities. This study identified a novel metabolic phenotype: "delayed-accumulator lesions" (DAL), characterized by significant SUV escalation between initial and delayed imaging, associated with aggressive biological behavior and poor prognostic outcomes. Additionally, a mathematical model incorporating dual-phase SUV kinetics, parametrial invasion status, and bilateral lymph node involvement demonstrated superior prognostic stratification (AUC > 0.92) compared to conventional FIGO staging.
Dual-phase [18F]FDG PET/CT provides significantly enhanced metabolic characterization of cervical cancer, identifies novel biological markers predictive of treatment response, and enables metabolically guided precision treatment planning. The identification of delayed-accumulator lesions and dual-phase kinetic modeling represent paradigm shifts in cervical cancer stratification, with the potential to revolutionize treatment intensity selection and surveillance protocols.
A prospective study of 50 patients with histopathologically proven cervical cancer was conducted over 24 months. Patients underwent dual-phase [18F]FDG PET/CT imaging with initial whole-body acquisition at 40-60 minutes post-injection and delayed imaging at 120 minutes post-injection following intravenous furosemide administration. Standardized uptake values (SUV), lesion detection efficacy, lymph node characterization, and extra-pelvic metastatic patterns were analyzed using paired t-tests and chi-square analysis.
Mean SUV in initial images (9.074 ± 6.113) increased significantly to 12.964 ± 7.494 in delayed images (p < 0.001), representing a 42.8% increase in metabolic activity. Delayed imaging detected primary lesions in 48 cases (96%) versus 44 cases (88%) on initial imaging, demonstrating superior sensitivity (91.7%) and specificity (100%). Critically, seven patients (14%) demonstrated lymph node visualization only on delayed imaging, and 14% exhibited SUV kinetics consistent with high-grade malignancy. Parametrial involvement occurred in 66% of cases, with 81.8% demonstrating bilateral involvement. Extra-pelvic metastases including supraclavicular lymphadenopathy (10%), hepatic involvement (10%), and skeletal lesions (8%) were detected with superior specificity compared to conventional modalities. This study identified a novel metabolic phenotype: "delayed-accumulator lesions" (DAL), characterized by significant SUV escalation between initial and delayed imaging, associated with aggressive biological behavior and poor prognostic outcomes. Additionally, a mathematical model incorporating dual-phase SUV kinetics, parametrial invasion status, and bilateral lymph node involvement demonstrated superior prognostic stratification (AUC > 0.92) compared to conventional FIGO staging.
Dual-phase [18F]FDG PET/CT provides significantly enhanced metabolic characterization of cervical cancer, identifies novel biological markers predictive of treatment response, and enables metabolically guided precision treatment planning. The identification of delayed-accumulator lesions and dual-phase kinetic modeling represent paradigm shifts in cervical cancer stratification, with the potential to revolutionize treatment intensity selection and surveillance protocols.
Authors
Vishnoi Vishnoi, Jain Jain, Akhariya Akhariya, Balaan Balaan, Solanki Solanki, Bushra Bushra
View on Pubmed